A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ulka N. Vaishampayan, David F. McDermott, Marc Ryan Matrana, Sun Young Rha, Amado J. Zurita, Thai Huu Ho, Bhumsuk Keam, Jae-Lyun Lee, Richard Wayne Joseph, Sarah Ali, Walter Michael Stadler, Naomi B. Haas, Srinath Sundararajan, Se Hoon Park, Rex B. Mowat, Joel Picus, Arkadiusz Z. Dudek, Yousef Zakharia, Lu Gan, Michael B. Atkins
Institutions: The Barbara Ann Karmanos Cancer Institute, Beth Israel Deaconess Medical Center, Ochsner Medical Center, Yonsei University, Yonsei University Health System, The University of Texas MD Anderson Cancer Center, Mayo Clinic in Arizona, Seoul National University Hospital, Asan Medical Center, University of Ulsan, Mayo Clinic in Florida, Michigan State University, University of Chicago, Abramson Cancer Center, University of Arizona Cancer Center, Samsung Medical Center, Sungkyunkwan University, Washington University in St. Louis, HealthPartners, University of Iowa Hospitals and Clinics, University of Iowa Health Care, University of Iowa Holden Comprehensive Cancer Center, X4 Pharmaceuticals, Inc. (United States), Georgetown University Medical Center, MedStar Georgetown University Hospital, Georgetown Lombardi Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891016361